BIEL + Electrome: The First Public‑Market Gateway Into the “AI Billionaire Wave”
The AI boom has created enormous wealth — but almost all of it has been locked behind private markets. Companies like OpenAI, Anthropic, Inflection, and xAI minted billionaires long before the public ever had a chance to invest.
Normally, only:
Venture capital firms
Silicon Valley insiders
Private equity
Accredited investors
…get access to early‑stage, category‑defining AI opportunities.
But the convergence of BIEL + Electrome + Ken Mayer is different.
Because BIEL is publicly traded, everyday investors can participate in a potential AI‑platform breakout before the valuation surge — something almost unheard of in the AI sector.
And the timing couldn’t be better.
FDA Deregulation Has Created the Same Conditions That Minted Today’s AI Billionaires
The FDA’s new stance — exempting non‑medical‑grade wearable data from regulation — has opened the exact environment that allowed early AI giants to explode in value:
Low regulatory friction
High storytelling leverage
Massive data potential
AI‑driven narratives
Platform‑level positioning
This is the same environment that minted billionaires behind companies that often had:
No product
No revenue
Sometimes not even a prototype
Just a compelling AI story and a data‑centric vision.
BIEL + Electrome are uniquely positioned to ride this wave — together, not separately.
The Missing Pieces: Electrome and Ken Mayer
BIEL has the hardware.
ActiPatch has the therapy.
But to become an AI‑native wearable platform, two things were missing:
A brain (Electrome)
A story (Ken Mayer)
Together, they transform ActiPatch from a static OTC device into a scalable AI ecosystem.
A Brief Summary: How ActiPatch Evolves Into an AI‑Ready Smart Wearable
ActiPatch today is:
An OTC wearable for musculoskeletal pain
Using pulsed shortwave / radiofrequency (PEMF)
Simple, non‑sensory, no data, no connectivity
It’s “dumb but effective” hardware — perfect for upgrading.
The Smart ActiPatch Blueprint (Condensed)
1. Collect the right data
Low‑friction, high‑signal data:
Usage (on/off, duration, adherence)
Body‑area context (back, knee, neck, etc.)
Therapy mode
Motion & posture via accelerometer
Optional biosignals later (temperature, skin conductance, heart rate)
This creates the minimum viable dataset for AI models.
2. Add a smart hardware layer
Without changing the patch’s identity:
Microcontroller (MCU)
BLE chip
Accelerometer + temperature sensor
Optional EDA/heart‑rate later
Slightly larger battery + power management
A tiny “smart pod” containing electronics
The flexible loop still delivers PEMF — the feel stays the same.
3. Build the software ecosystem
Companion app:
Pairing
Pain‑area selection
Session tracking
Pain scores
Sleep/activity tolerance
Firmware updates
Cloud layer:
Anonymized data
Usage patterns
Movement correlations
Condition‑specific outcomes
AI training foundation
Executed at scale, this becomes the world’s largest dataset on real‑world non‑drug pain modulation.
4. Keep the user experience stupid‑simple
Stick it on
Press start
App runs quietly in the background
Optional 10‑second check‑ins
Gentle nudges
The tech stays invisible; the benefit stays obvious.
5. Regulatory strategy
Phase 1: Wellness wearable
Track use, activity, self‑reported pain
No medical claims
Move fast under FDA exemption
Phase 2: Real‑world evidence + AI
Train predictive models
Inform future 510(k) submissions
Build “ActiPatch Clinical” SKUs
6. Investor narrative unlocked
ActiPatch becomes:
A data node
A global bioelectric network
A subscription platform
An AI‑powered therapeutic ecosystem
This is the evolution that justifies massive valuation step‑ups.
1. Reframe From “Device Maker” to an AI‑Driven Bioelectronic Platform
AI billionaires don’t build products — they build platforms.
Right now:
BIEL looks like a device manufacturer
Electrome looks like an AI‑driven bioelectric company
Together, they become:
“The world’s first AI‑powered bioelectronic pain‑modulation platform.”
This instantly reframes the company as:
Data‑driven
Scalable
Software‑enhanced
AI‑enabled
Platform‑level
Exactly the type of narrative that attracts billion‑dollar valuations.
2. Electrome Provides the “Brain” ActiPatch Never Had
Electrome brings:
AI + Signal Processing
Motion/posture interpretation
Predictive pain‑flare modeling
Adaptive therapy loops
Data Architecture
Cloud pipelines
Secure ingestion
Real‑time analytics
Wearable Integration
BLE (Bluetooth Low Energy)
Sensor fusion
Low‑power firmware
Electrome turns ActiPatch into a smart node in a bioelectric network, not just a patch.
3. Build a Billionaire‑Style Data Narrative
AI billionaires raise money on data potential, not finished AI.
BIEL already has:
1M+ devices sold
Years of usage data
Clinical trials
Real‑world outcomes
Electrome adds:
AI modeling
Digital twins
Bioelectric signal interpretation
Together, they can credibly claim:
“We are building the world’s largest dataset on non‑pharmaceutical pain modulation.”
That alone is an investor magnet.
4. Introduce Predictive Pain AI — The Billionaire Maker
Electrome can develop:
Pain‑flare prediction
Personalized stimulation
Adaptive therapy loops
AI‑guided recovery plans
This is exactly how pre‑product AI startups reach billion‑dollar valuations.
5. Ken Mayer Provides the Vision, Positioning, and AI Narrative
Ken Mayer turns the transformation into a category‑creating story.
Brand Positioning
ActiPatch → ActiPatch Smart → ActiPatch AI
“Bioelectric wellness” as a category
Investor Narrative
Data flywheel
Predictive AI
Personalized therapy
Subscription economics
Strategic Partnerships
AI labs
Digital health accelerators
Wearable companies
Ken is the bridge between hardware, AI, investors, and regulators.
6. Move at “AI Speed” Under FDA Deregulation
The FDA now encourages:
AI‑driven wellness
Non‑medical‑grade data
Market‑driven innovation
This lets BIEL + Electrome:
Launch faster
Iterate faster
Collect data faster
Scale faster
Exactly how AI billionaires emerged.
7. Build a Subscription‑Based AI Wellness Platform
AI unicorns thrive on:
Recurring revenue
Software margins
Predictive analytics
Electrome can build:
AI‑driven therapy recommendations
Personalized recovery plans
Monthly analytics reports
ActiPatch becomes the hardware gateway to a recurring‑revenue AI ecosystem.
8. Tell a Billionaire‑Scale Story — Bigger Than the Product
AI billionaires don’t sell devices.
They sell:
A future
A paradigm shift
A new category
Together, BIEL + Electrome can position themselves as:
“The AI‑powered future of non‑drug pain relief.”
Investors understand this narrative — and fund it aggressively.
Why Collaboration Creates Billionaire‑Level Upside
BIEL Alone
Strong hardware
Large user base
Limited AI narrative
Electrome Alone
Strong AI vision
No mass‑market hardware
No large dataset
Together
Hardware + Software = Platform
Scale + Intelligence = Defensibility
Data + AI = Billionaire narrative
Wellness + FDA deregulation = Speed
Unified ecosystem = High switching costs
This is the formula that minted AI billionaires.
The “AI Billionaire” Moment Is Now
FDA deregulation means:
Move fast
Collect data
Build AI loops
Launch wellness products
Scale before competitors clear regulatory hurdles
This is the exact environment that allowed:
OpenAI
Anthropic
Inflection
xAI
HuggingFace
…to mint billionaires with early‑stage visions.
BIEL + Electrome can do the same in the bioelectric wellness category — a space with far less competition and far more unmet need.
The AI boom has created enormous wealth — but almost all of it has been locked behind private markets. Companies like OpenAI, Anthropic, Inflection, and xAI minted billionaires long before the public ever had a chance to invest.
Normally, only:
Venture capital firms
Silicon Valley insiders
Private equity
Accredited investors
…get access to early‑stage, category‑defining AI opportunities.
But the convergence of BIEL + Electrome + Ken Mayer is different.
Because BIEL is publicly traded, everyday investors can participate in a potential AI‑platform breakout before the valuation surge — something almost unheard of in the AI sector.
And the timing couldn’t be better.
FDA Deregulation Has Created the Same Conditions That Minted Today’s AI Billionaires
The FDA’s new stance — exempting non‑medical‑grade wearable data from regulation — has opened the exact environment that allowed early AI giants to explode in value:
Low regulatory friction
High storytelling leverage
Massive data potential
AI‑driven narratives
Platform‑level positioning
This is the same environment that minted billionaires behind companies that often had:
No product
No revenue
Sometimes not even a prototype
Just a compelling AI story and a data‑centric vision.
BIEL + Electrome are uniquely positioned to ride this wave — together, not separately.
The Missing Pieces: Electrome and Ken Mayer
BIEL has the hardware.
ActiPatch has the therapy.
But to become an AI‑native wearable platform, two things were missing:
A brain (Electrome)
A story (Ken Mayer)
Together, they transform ActiPatch from a static OTC device into a scalable AI ecosystem.
A Brief Summary: How ActiPatch Evolves Into an AI‑Ready Smart Wearable
ActiPatch today is:
An OTC wearable for musculoskeletal pain
Using pulsed shortwave / radiofrequency (PEMF)
Simple, non‑sensory, no data, no connectivity
It’s “dumb but effective” hardware — perfect for upgrading.
The Smart ActiPatch Blueprint (Condensed)
1. Collect the right data
Low‑friction, high‑signal data:
Usage (on/off, duration, adherence)
Body‑area context (back, knee, neck, etc.)
Therapy mode
Motion & posture via accelerometer
Optional biosignals later (temperature, skin conductance, heart rate)
This creates the minimum viable dataset for AI models.
2. Add a smart hardware layer
Without changing the patch’s identity:
Microcontroller (MCU)
BLE chip
Accelerometer + temperature sensor
Optional EDA/heart‑rate later
Slightly larger battery + power management
A tiny “smart pod” containing electronics
The flexible loop still delivers PEMF — the feel stays the same.
3. Build the software ecosystem
Companion app:
Pairing
Pain‑area selection
Session tracking
Pain scores
Sleep/activity tolerance
Firmware updates
Cloud layer:
Anonymized data
Usage patterns
Movement correlations
Condition‑specific outcomes
AI training foundation
Executed at scale, this becomes the world’s largest dataset on real‑world non‑drug pain modulation.
4. Keep the user experience stupid‑simple
Stick it on
Press start
App runs quietly in the background
Optional 10‑second check‑ins
Gentle nudges
The tech stays invisible; the benefit stays obvious.
5. Regulatory strategy
Phase 1: Wellness wearable
Track use, activity, self‑reported pain
No medical claims
Move fast under FDA exemption
Phase 2: Real‑world evidence + AI
Train predictive models
Inform future 510(k) submissions
Build “ActiPatch Clinical” SKUs
6. Investor narrative unlocked
ActiPatch becomes:
A data node
A global bioelectric network
A subscription platform
An AI‑powered therapeutic ecosystem
This is the evolution that justifies massive valuation step‑ups.
1. Reframe From “Device Maker” to an AI‑Driven Bioelectronic Platform
AI billionaires don’t build products — they build platforms.
Right now:
BIEL looks like a device manufacturer
Electrome looks like an AI‑driven bioelectric company
Together, they become:
“The world’s first AI‑powered bioelectronic pain‑modulation platform.”
This instantly reframes the company as:
Data‑driven
Scalable
Software‑enhanced
AI‑enabled
Platform‑level
Exactly the type of narrative that attracts billion‑dollar valuations.
2. Electrome Provides the “Brain” ActiPatch Never Had
Electrome brings:
AI + Signal Processing
Motion/posture interpretation
Predictive pain‑flare modeling
Adaptive therapy loops
Data Architecture
Cloud pipelines
Secure ingestion
Real‑time analytics
Wearable Integration
BLE (Bluetooth Low Energy)
Sensor fusion
Low‑power firmware
Electrome turns ActiPatch into a smart node in a bioelectric network, not just a patch.
3. Build a Billionaire‑Style Data Narrative
AI billionaires raise money on data potential, not finished AI.
BIEL already has:
1M+ devices sold
Years of usage data
Clinical trials
Real‑world outcomes
Electrome adds:
AI modeling
Digital twins
Bioelectric signal interpretation
Together, they can credibly claim:
“We are building the world’s largest dataset on non‑pharmaceutical pain modulation.”
That alone is an investor magnet.
4. Introduce Predictive Pain AI — The Billionaire Maker
Electrome can develop:
Pain‑flare prediction
Personalized stimulation
Adaptive therapy loops
AI‑guided recovery plans
This is exactly how pre‑product AI startups reach billion‑dollar valuations.
5. Ken Mayer Provides the Vision, Positioning, and AI Narrative
Ken Mayer turns the transformation into a category‑creating story.
Brand Positioning
ActiPatch → ActiPatch Smart → ActiPatch AI
“Bioelectric wellness” as a category
Investor Narrative
Data flywheel
Predictive AI
Personalized therapy
Subscription economics
Strategic Partnerships
AI labs
Digital health accelerators
Wearable companies
Ken is the bridge between hardware, AI, investors, and regulators.
6. Move at “AI Speed” Under FDA Deregulation
The FDA now encourages:
AI‑driven wellness
Non‑medical‑grade data
Market‑driven innovation
This lets BIEL + Electrome:
Launch faster
Iterate faster
Collect data faster
Scale faster
Exactly how AI billionaires emerged.
7. Build a Subscription‑Based AI Wellness Platform
AI unicorns thrive on:
Recurring revenue
Software margins
Predictive analytics
Electrome can build:
AI‑driven therapy recommendations
Personalized recovery plans
Monthly analytics reports
ActiPatch becomes the hardware gateway to a recurring‑revenue AI ecosystem.
8. Tell a Billionaire‑Scale Story — Bigger Than the Product
AI billionaires don’t sell devices.
They sell:
A future
A paradigm shift
A new category
Together, BIEL + Electrome can position themselves as:
“The AI‑powered future of non‑drug pain relief.”
Investors understand this narrative — and fund it aggressively.
Why Collaboration Creates Billionaire‑Level Upside
BIEL Alone
Strong hardware
Large user base
Limited AI narrative
Electrome Alone
Strong AI vision
No mass‑market hardware
No large dataset
Together
Hardware + Software = Platform
Scale + Intelligence = Defensibility
Data + AI = Billionaire narrative
Wellness + FDA deregulation = Speed
Unified ecosystem = High switching costs
This is the formula that minted AI billionaires.
The “AI Billionaire” Moment Is Now
FDA deregulation means:
Move fast
Collect data
Build AI loops
Launch wellness products
Scale before competitors clear regulatory hurdles
This is the exact environment that allowed:
OpenAI
Anthropic
Inflection
xAI
HuggingFace
…to mint billionaires with early‑stage visions.
BIEL + Electrome can do the same in the bioelectric wellness category — a space with far less competition and far more unmet need.
